ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 82 citations in OpenAlex.
- Structural characteristics and SARs of EZH2 inhibitors.Molecular diversity · 2026Review
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
- Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling.Cancer reports (Hoboken, N.J.) · 2026Article
- Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications.Molecular biomedicine · 2025Review
- AKR1B1 is Required for Maintaining Acute Leukemia Cell Survival by Epigenetic Silencing of Tumor Suppressor Genes.Biochemical genetics · 2025Article
- Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation.Nature communications · 2025Article
- p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance.Nature communications · 2025Article
- A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma.Journal of hematology & oncology · 2025Article
- Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.Functional & integrative genomics · 2025Review
- Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.The Lancet. Oncology · 2024Article
- Multiple myeloma: signaling pathways and targeted therapy.Molecular biomedicine · 2024Review
- Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.Experimental hematology & oncology · 2023Article
- Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells.International journal of molecular sciences · 2023Review
- Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.Translational oncology · 2022Article
- Article
- Liver group 2 innate lymphoid cells regulate blood glucose levels through IL-13 signaling and suppression of gluconeogenesis.Nature communications · 2022Article
- Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation.The Journal of clinical investigation · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Ola RizqDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Naoya MimuraDepartment of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan. naoyamimura@chiba-u.jp aiwama@faculty.chiba-u.jp.
Motohiko OshimaDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Atsunori SarayaDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Shuhei KoideDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Yuko KatoDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Kazumasa AoyamaDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Yaeko Nakajima-TakagiDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Changshan WangDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Tetsuhiro ChibaDepartment of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine, Chiba, Japan.
Anqi MaDepartments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Jian JinDepartments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Tohru IsekiDepartment of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Atsushi IwamaDepartment of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. naoyamimura@chiba-u.jp aiwama@faculty.chiba-u.jp.
Chiba University · JPChiba University Hospital · JPIcahn School of Medicine at Mount Sinai · US
Funding
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged LeukemiasR01CA218600 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN, WANG, G GREG · 2017 to 2021
$2.8MDiscovery of Selective Inhibitors for Histone MethyltransferasesR01GM122749 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN · 2017 to 2020
$1.3MCreating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLPR01GM103893 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JIN, JIAN · 2013 to 2015
$1.1MNCI NIH HHS R01 CA218600NIGMS NIH HHS R01 GM103893NIGMS NIH HHS R01 GM122749
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBortezomibCell Line, TumorCells, CulturedDrug SynergismEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHumansIndazolesMaleMice, Inbred NODMice, KnockoutMice, SCIDMultiple MyelomaBenzamidesBortezomibEnhancer of Zeste Homolog 2 ProteinEZH1 protein, humanEZH2 protein, humanIndazolesPiperazinesPolycomb Repressive Complex 2Proteasome Endopeptidase ComplexProteasome InhibitorsPyridonesUNC1999
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.